Geode Capital Management
TOVX icon

Geode Capital Management’s Theriva Biologics TOVX Stock Holding History

Geode Capital Management’s Portfolio TOVX Stock Details TOVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$88.2K Buy
450,263
+238,176
+112% +$46.9K ﹤0.01% 4166
2025
Q4 		$44.6K Buy
212,087
+183,878
+652% +$54.4K ﹤0.01% 4256
2025
Q3 		$11.4K Buy
28,209
+9,608
+52% +$4.16K ﹤0.01% 4441
2025
Q2 		$8.07K Sell
18,601
-82
-0.4% -$67 ﹤0.01% 4427
2025
Q1 		$20.6K Buy
+18,683
New +$26.1K ﹤0.01% 4338
2024
Q3 		– Sell
-5,647
Closed -$33.4K – 4582
2024
Q2 		$33.4K Hold
5,647
– – ﹤0.01% 4365
2024
Q1 		$66.2K Hold
5,647
– – ﹤0.01% 4263
2023
Q4 		$60.7K Hold
5,647
– – ﹤0.01% 4305
2023
Q3 		$76.2K Buy
5,647
+995
+21% +$15.1K ﹤0.01% 4320
2023
Q2 		$116K Hold
4,652
– – ﹤0.01% 4277
2023
Q1 		$81.2K Hold
4,652
– – ﹤0.01% 4406
2022
Q4 		$52K Sell
4,652
-11
-0.2% -$200 ﹤0.01% 4580
2022
Q3 		$114K Hold
4,663
– – ﹤0.01% 4517
2022
Q2 		$248K Buy
4,663
+151
+3% +$8.64K ﹤0.01% 4137
2022
Q1 		$321K Buy
4,512
+607
+16% +$41.4K ﹤0.01% 4151
2021
Q4 		$265K Hold
3,905
– – ﹤0.01% 4350
2021
Q3 		$448K Buy
3,905
+80
+2% +$9.96K ﹤0.01% 4083
2021
Q2 		$576K Buy
3,825
+383
+11% +$54.9K ﹤0.01% 3874
2021
Q1 		$586K Buy
3,442
+3,371
+4,748% +$666K ﹤0.01% 3751
2020
Q4 		$6K Hold
71
– – ﹤0.01% 4267
2020
Q3 		$8K Hold
71
– – ﹤0.01% 4151
2020
Q2 		$9K Hold
71
– – ﹤0.01% 4093
2020
Q1 		$5K Hold
71
– – ﹤0.01% 4101
2019
Q4 		$8K Hold
71
– – ﹤0.01% 4198
2019
Q3 		$8K Hold
71
– – ﹤0.01% 4181
2019
Q2 		$9K Hold
71
– – ﹤0.01% 4190
2019
Q1 		$11K Hold
71
– – ﹤0.01% 4118
2018
Q4 		$9K Hold
71
– – ﹤0.01% 4130
2018
Q3 		$45K Hold
71
– – ﹤0.01% 4035
2018
Q2 		$147K Hold
71
– – ﹤0.01% 3793
2018
Q1 		$196K Hold
71
– – ﹤0.01% 3698
2017
Q4 		$313K Buy
71
+13
+22% +$81.2K ﹤0.01% 3521
2017
Q3 		$474K Buy
58
+12
+26% +$69.4K ﹤0.01% 3384
2017
Q2 		$225K Sell
46
-17
-27% -$84.7K ﹤0.01% 3640
2017
Q1 		$347K Buy
63
+2
+3% +$14K ﹤0.01% 3455
2016
Q4 		$409K Buy
61
+4
+7% +$41.1K ﹤0.01% 3343
2016
Q3 		$850K Buy
57
+1
+2% +$15K ﹤0.01% 3025
2016
Q2 		$878K Buy
56
+10
+22% +$188K ﹤0.01% 2968
2016
Q1 		$942 Buy
46
+5
+12% +$75.2K ﹤0.01% 2908
2015
Q4 		$813K Hold
41
– – ﹤0.01% 3022
2015
Q3 		$806K Buy
41
+8
+24% +$197K ﹤0.01% 2988
2015
Q2 		$830K Buy
33
+4
+14% +$80.3K ﹤0.01% 2992
2015
Q1 		$553K Hold
29
– – ﹤0.01% 3154
2014
Q4 		$369K Buy
29
+9
+45% +$121K ﹤0.01% 3323
2014
Q3 		$309K Buy
20
+3
+18% +$48.8K ﹤0.01% 3386
2014
Q2 		$256K Hold
17
– – ﹤0.01% 3431
2014
Q1 		$383K Buy
17
+6
+55% +$124K ﹤0.01% 3262
2013
Q4 		$150K Hold
11
– – ﹤0.01% 3506
2013
Q3 		$165K Hold
11
– – ﹤0.01% 3371
2013
Q2 		$169K Buy
+11
New +$150K ﹤0.01% 3279

Other funds holding TOVX

VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Geode Capital Management's TOVX Position: Q1 2026 in Review

Geode Capital Management increased its Theriva Biologics (TOVX) stake by 112% in Q1 2026, buying an estimated $46.9K and bringing the position to 450,263 shares worth $88.2K. The position accounts for ﹤0.01% of the portfolio, ranked #4166.

Geode Capital Management first reported a position in TOVX in Q2 2013 and has held it in 50 quarters since. The position peaked at $878K in Q2 2016. 22 funds tracked by Wall St. Rank hold TOVX as of Q1 2026.

  • Geode Capital Management held 450,263 shares of Theriva Biologics worth $88.2K as of Q1 2026.
  • Geode Capital Management bought 238,176 Theriva Biologics shares in Q1 2026, an estimated $46.9K.
  • Theriva Biologics made up ﹤0.01% of Geode Capital Management's portfolio in Q1 2026, its #4166 holding.
  • Geode Capital Management first reported a position in Theriva Biologics in Q2 2013 and has held it in 50 quarters since.
  • Geode Capital Management's Theriva Biologics position peaked at $878K in Q2 2016.
  • 22 funds tracked by Wall St. Rank held Theriva Biologics as of Q1 2026.

Based on Geode Capital Management's 13F filing for Q1 2026, filed 15 May 2026.